Opioid Use & Corneal Cross-Linking: Reducing Reliance in Ophthalmology

The Shifting Landscape of Pain Management in Corneal Cross-Linking

The opioid epidemic has cast a long shadow over all areas of healthcare, and ophthalmology is no exception. While postoperative opioid prescriptions following ophthalmic procedures are generally low-dose, the potential for harm – including hospitalization, overdose, and even mortality – remains a significant concern. Recent data highlights the need for a reevaluation of pain management protocols, particularly in procedures like corneal cross-linking (CXL).

The Unique Pain Profile of CXL

Corneal cross-linking, a common treatment for keratoconus, presents a unique pain management challenge. The cornea is the most densely innervated tissue in the human body. In CXL, the removal of the corneal epithelium exposes these nerve endings, and the subsequent ultraviolet A-induced stromal injury intensifies discomfort. Postoperative pain typically peaks within the first 24 to 72 hours and is often described as excruciating.

Variability in Prescribing Practices & The Role of Training

Despite the recognized need for cautious opioid use, significant variability exists in prescribing practices. A 2025 study from Massachusetts Eye and Ear found that 2.2% of all ophthalmic procedures resulted in an opioid prescription, with cornea specialists accounting for roughly one-third of those. Notably, over half of these prescriptions were written by fellows and residents, underscoring the critical role of trainee education in shaping prescribing patterns.

Moving Towards Opioid-Sparing Therapies

The ophthalmic field is actively exploring opioid-sparing alternatives. Multimodal regimens, combining non-opioid analgesics like NSAIDs and acetaminophen, are gaining traction. Beyond pharmacologic approaches, innovative techniques like “epi-on” CXL – which leaves the corneal epithelium intact – show promise in reducing postoperative discomfort and, the need for opioid prescriptions.

The Promise of Standardized Guidelines

Currently, no standardized guidelines exist for pain management following CXL. This lack of consensus contributes to the observed variability in prescription frequency. Initiatives like the one implemented at the Mayo Clinic, which categorized surgeries based on expected opioid needs, demonstrate the potential for significant reductions in both opioid dose and prescribing frequency without compromising patient outcomes.

Beyond CXL: A Broader Trend in Ophthalmology

The focus on opioid stewardship extends beyond CXL. Similar efforts are underway to optimize pain management protocols for other ophthalmic procedures, recognizing that even low-dose, short-course opioid regimens can carry risks. The development of specialty-specific prescribing protocols, informed by evidence-based research, is crucial for driving this change.

Did you recognize?

Even a single opioid prescription after ophthalmic surgery has been linked to higher rates of hospitalization, overdose, and mortality.

FAQ: Opioid Use and Corneal Cross-Linking

• Q: Is opioid pain medication always necessary after CXL?
  A: No. Increasingly, multimodal pain management strategies and techniques like epi-on CXL are reducing the need for opioids.
• Q: What are the risks of taking opioids after CXL?
  A: Even short-term opioid use can carry risks, including dependence, overdose, and increased mortality.
• Q: What can I do to manage pain after CXL without opioids?
  A: Discuss non-opioid pain management options with your surgeon, such as NSAIDs, acetaminophen, and topical anesthetics.

As the indications for CXL continue to expand, a commitment to evidence-based, standardized approaches that prioritize both patient comfort and safety is paramount. Managing CXL pain effectively, while minimizing exposure to the potential harms of opioids, remains a critical challenge for cornea specialists.